Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Efstathiou

Showing results (121-130 of 278) with videos related to

Pageof 28
Sort By:
Urologic Oncology|February 1, 2023
Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancerSagar A Patel, Yuan Liu, Abhishek A Solanki, et al.
The Oncologist|June 15, 2014
Cervical brachytherapy exchange: steps toward oncology capacity building in BotswanaMemory Bvochara-Nsingo, Surbhi Grover, David P Gierga, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2010
Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancerAlexei Trofimov, Paul L Nguyen, Jason A Efstathiou, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2010
Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trialPaul L Nguyen, Ronald C Chen, Karen E Hoffman, et al.
Journal of Oncology Practice|January 9, 2014
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancerAyal A Aizer, Jonathan J Paly, M Dror Michaelson, et al.
Bladder Cancer (Amsterdam, Netherlands)|November 4, 2024
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder CancerParminder Singh, Leslie Ballas, Guru P Sonpavde, et al.
Fertility and Sterility|October 8, 2005
Endostatin inhibits the growth of endometriotic lesions but does not affect fertilityChristian M Becker, David A Sampson, Maria A Rupnick, et al.
International Journal of Radiation Oncology, Biology, Physics|March 12, 2013
Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancerJohn J Coen, Jonathan J Paly, Andrzej Niemierko, et al.
Clinical Genitourinary Cancer|December 22, 2024
Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder CancerNikhil V Kotha, Abhishek Kumar, Paul Riviere, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality TherapyYukako Otani, Keisuke Otani, Daniel Rodden, et al.
Pageof 28

Showing results (121-130 of 278) with videos related to

Sort By:
Pageof 28
Urologic Oncology|February 1, 2023
Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancerSagar A Patel, Yuan Liu, Abhishek A Solanki, et al.
The Oncologist|June 15, 2014
Cervical brachytherapy exchange: steps toward oncology capacity building in BotswanaMemory Bvochara-Nsingo, Surbhi Grover, David P Gierga, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2010
Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancerAlexei Trofimov, Paul L Nguyen, Jason A Efstathiou, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2010
Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trialPaul L Nguyen, Ronald C Chen, Karen E Hoffman, et al.
Journal of Oncology Practice|January 9, 2014
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancerAyal A Aizer, Jonathan J Paly, M Dror Michaelson, et al.
Bladder Cancer (Amsterdam, Netherlands)|November 4, 2024
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder CancerParminder Singh, Leslie Ballas, Guru P Sonpavde, et al.
Fertility and Sterility|October 8, 2005
Endostatin inhibits the growth of endometriotic lesions but does not affect fertilityChristian M Becker, David A Sampson, Maria A Rupnick, et al.
International Journal of Radiation Oncology, Biology, Physics|March 12, 2013
Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancerJohn J Coen, Jonathan J Paly, Andrzej Niemierko, et al.
Clinical Genitourinary Cancer|December 22, 2024
Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder CancerNikhil V Kotha, Abhishek Kumar, Paul Riviere, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality TherapyYukako Otani, Keisuke Otani, Daniel Rodden, et al.
Pageof 28